Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha V beta 6

Integrin alpha V beta 6

Brief Information

Name:Integrin alpha-V/beta-6
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 Integrin alpha V beta 6 ELISA

Immobilized Mouse Latent TGFB1, His Tag (Cat. No. TG1-M5245) at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-M82W9) with a linear range of 1-20 ng/mL (QC tested).

Integrin alpha V beta 6 MALS images

The purity of Rat ITGAV&ITGB6 Heterodimer, His Tag&Tag Free (Cat. No. IT6-R52E6) is more than 85% and the molecular weight of this protein is around 242-272 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

Integrin alpha V beta 6,ITGAV&ITGB6


Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Bexotegrast PLN-74809 Phase 3 Clinical Pliant Therapeutics Inc Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Cholangitis, Sclerosing Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Inc Metabolic Dysfunction-Associated Steatotic Liver Disease; Idiopathic Pulmonary Fibrosis Details
Nesvategrast OTT-166(OcuTerra Therapeutics); SF-0166 Phase 2 Clinical Scifluor Life Sciences Inc, OcuTerra Therapeutics Inc Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration Details
18F-αvβ6-Binding-Peptide 18F-αvβ6-BP Phase 1 Clinical National Cancer Institute, National Institutes Of Health Rectal Neoplasms; Colonic Neoplasms; Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Coronaviridae Infections; Lung Neoplasms; Metastatic breast cancer Details
[18F]FP-R01-MG [18F]FP-R01-MG; [18F]FP-R01-MG-F2 Phase 1 Clinical Pliant Therapeutics Inc, Stanford University, Chinese Academy Of Medical Science & Peking Union Medical College Small Cell Lung Carcinoma; Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Cholangitis, Sclerosing; Brain metastases; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ga-68-Trivehexin RAD-301 Phase 1 Clinical Trimt GmbH Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message